Get my own profile
Public access
View all41 articles
7 articles
available
not available
Based on funding mandates
Co-authors
- Ola EngkvistAstraZeneca R&D Gothenburg Orcid:0000-0003-4970-6461Verified email at astrazeneca.com
- Lars CarlssonRTHS and CRML, University of LondonVerified email at rhul.ac.uk
- Thierry KogejAssociate Principal Scientist, AstraZenecaVerified email at astrazeneca.com
- Sorel MuresanR&D Manager HPC EMEA, Nouryon, Stenungsund SwedenVerified email at nouryon.com
- Jiangming SunLund UniversityVerified email at med.lu.se
- Yidong YangMolecular Oncology, BC Cancer Research CentreVerified email at bccrc.ca
- Igor V. TetkoBIGCHEM GmbH & Helmholtz MunichVerified email at helmholtz-munich.de
- John G. Cumming, PhDExperienced medicinal chemist, AstraZeneca PharmaceuticalsVerified email at astrazeneca.com
- Niklas BlombergDirector, ELIXIRVerified email at ebi.ac.uk
- Andrew M DavisAstraZeneca, Fisons, Astra, University of KentVerified email at astrazeneca.com
- Markus FridenRIA iMed, AstraZenecaVerified email at astrazeneca.com
- Antonio LlinŕsRIA iMed AstraZenecaVerified email at astrazeneca.com
- JG KennaPharmaceutical DirectorVerified email at safermedicines.org
- Daniel WarnerSilverstripe Credit and Technologies, London, UK.Verified email at plata.com
- Antonsson MadeleineAstraZenecaVerified email at astrazeneca.com
- Mats SvenssonVerified email at schrodinger.com
Follow
Hongming Chen
Astrazeneca, Bioland Laboratory, Guangzhou Laboratory
Verified email at grmh-gdl.cn